StreetInsider.com News Articles

Form SCHEDULE 13G Maywood Acquisition Corp Filed by: WOLVERINE ASSET MANAGEMENT LLC

Tue, 14 Jul 2026 10:53:00 -0400

si-local-file:///var/storage/secattach/20260714/26766587.html

Termination of Proposed Acquisition of Mayne Pharma

Thu, 11 Dec 2025 17:57:00 -0400

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Cosette Pharmaceuticals, Inc. (Cosette), a U.S.-based, fully integrated pharmaceutical company, confirms that on 9 December 2025 it served a notice on Mayne Pharma Group Limited (Mayne Pharma, ASX: Ticker MYX) terminating the agreement between Cosette and Mayne Pharma under which Cosette was to acquire all the outstanding shares of Mayne Pharma (Scheme Implementation Deed). Cosette also notes the announcements from Mayne Pharma on 10 December 2025 and 11 December 2025 and confirms that on 11 December 2025 Mayne Pharma served its own notice of termination of the Scheme Implementation Deed on Cosette.

Both parties’ notices

Termination of Proposed Acquisition of Mayne Pharma

Thu, 11 Dec 2025 17:57:00 -0400

Both parties’ notices

Termination of Proposed Acquisition of Mayne Pharma

Thu, 11 Dec 2025 17:57:00 -0400

Both parties’ notices

Termination of Proposed Acquisition of Mayne Pharma

Thu, 11 Dec 2025 17:57:00 -0400

Both parties’ notices

Termination of Proposed Acquisition of Mayne Pharma

Thu, 11 Dec 2025 17:57:00 -0400

Both parties’ notices

Termination of Proposed Acquisition of Mayne Pharma

Thu, 11 Dec 2025 17:57:00 -0400

Both parties’ notices

Termination of Proposed Acquisition of Mayne Pharma

Thu, 11 Dec 2025 17:57:00 -0400

Both parties’ notices

Termination of Proposed Acquisition of Mayne Pharma

Thu, 11 Dec 2025 17:57:00 -0400

Both parties’ notices

Sol-Gel Technologies Ltd. (SLGL) sells U.S. rights for EPSOLAY and TWYNEO

Thu, 17 Apr 2025 08:42:25 -0400

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, today announced it has entered into a product purchase agreement with a subsidiary of Mayne Pharma Group Limited (ASX: MYX) for the sale and exclusive license of the U.S. rights to EPSOLAY and TWYNEO. Under the terms of the agreement, Sol-Gel will receive a total of $16 million in two installments: $10 million in the second quarter of 2025 and $6 million in the fourth quarter of 2025, which is expected to extend the Company’s cash runway into the first quarter of 2027. This agreement was executed following the mutual termination

Sol-Gel Technologies Ltd. (SLGL) sells U.S. rights for EPSOLAY and TWYNEO

Thu, 17 Apr 2025 08:42:25 -0400

Sol-Gel Technologies Ltd. (SLGL) sells U.S. rights for EPSOLAY and TWYNEO

Thu, 17 Apr 2025 08:42:25 -0400

Sol-Gel Technologies Ltd. (SLGL) sells U.S. rights for EPSOLAY and TWYNEO

Thu, 17 Apr 2025 08:42:25 -0400

Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.

Thu, 17 Apr 2025 08:40:00 -0400

Sol-Gel to receive $16 million during 2025
Cash runway is expected to extend into the first quarter of 2027; Company expects to have sufficient cash to complete its Phase III clinical trial
SGT-610 Phase III clinical trial top-line results are expected in the fourth quarter of 2026; a significant milestone in the clinical trial of recruiting more than 80% of the patients has been achieved
Sol-Gel now estimates the U.S. market potential for SGT-610 to be between $400 to $500 million annually
SGT-210 Phase 1b trial in Darier patients is ongoing; 50% of the patients have

Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.

Thu, 17 Apr 2025 08:40:00 -0400

Sol-Gel to receive $16 million during 2025
Cash runway is expected to extend into the first quarter of 2027; Company expects to have sufficient cash to complete its Phase III clinical trial
SGT-610 Phase III clinical trial top-line results are expected in the fourth quarter of 2026; a significant milestone in the clinical trial of recruiting more than 80% of the patients has been achieved
Sol-Gel now estimates the U.S. market potential for SGT-610 to be between $400 to $500 million annually
SGT-210 Phase 1b trial in Darier patients is ongoing; 50% of the patients have

Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.

Thu, 17 Apr 2025 08:40:00 -0400

Sol-Gel to receive $16 million during 2025
Cash runway is expected to extend into the first quarter of 2027; Company expects to have sufficient cash to complete its Phase III clinical trial
SGT-610 Phase III clinical trial top-line results are expected in the fourth quarter of 2026; a significant milestone in the clinical trial of recruiting more than 80% of the patients has been achieved
Sol-Gel now estimates the U.S. market potential for SGT-610 to be between $400 to $500 million annually
SGT-210 Phase 1b trial in Darier patients is ongoing; 50% of the patients have

Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.

Thu, 17 Apr 2025 08:40:00 -0400

Sol-Gel to receive $16 million during 2025
Cash runway is expected to extend into the first quarter of 2027; Company expects to have sufficient cash to complete its Phase III clinical trial
SGT-610 Phase III clinical trial top-line results are expected in the fourth quarter of 2026; a significant milestone in the clinical trial of recruiting more than 80% of the patients has been achieved
Sol-Gel now estimates the U.S. market potential for SGT-610 to be between $400 to $500 million annually
SGT-210 Phase 1b trial in Darier patients is ongoing; 50% of the patients have

Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.

Thu, 17 Apr 2025 08:40:00 -0400

Sol-Gel to receive $16 million during 2025
Cash runway is expected to extend into the first quarter of 2027; Company expects to have sufficient cash to complete its Phase III clinical trial
SGT-610 Phase III clinical trial top-line results are expected in the fourth quarter of 2026; a significant milestone in the clinical trial of recruiting more than 80% of the patients has been achieved
Sol-Gel now estimates the U.S. market potential for SGT-610 to be between $400 to $500 million annually
SGT-210 Phase 1b trial in Darier patients is ongoing; 50% of the patients have

Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.

Thu, 17 Apr 2025 08:40:00 -0400

Sol-Gel to receive $16 million during 2025
Cash runway is expected to extend into the first quarter of 2027; Company expects to have sufficient cash to complete its Phase III clinical trial
SGT-610 Phase III clinical trial top-line results are expected in the fourth quarter of 2026; a significant milestone in the clinical trial of recruiting more than 80% of the patients has been achieved
Sol-Gel now estimates the U.S. market potential for SGT-610 to be between $400 to $500 million annually
SGT-210 Phase 1b trial in Darier patients is ongoing; 50% of the patients have

Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.

Thu, 17 Apr 2025 08:40:00 -0400

Sol-Gel to receive $16 million during 2025
Cash runway is expected to extend into the first quarter of 2027; Company expects to have sufficient cash to complete its Phase III clinical trial
SGT-610 Phase III clinical trial top-line results are expected in the fourth quarter of 2026; a significant milestone in the clinical trial of recruiting more than 80% of the patients has been achieved
Sol-Gel now estimates the U.S. market potential for SGT-610 to be between $400 to $500 million annually
SGT-210 Phase 1b trial in Darier patients is ongoing; 50% of the patients have

Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.

Thu, 17 Apr 2025 08:40:00 -0400

Sol-Gel to receive $16 million during 2025
Cash runway is expected to extend into the first quarter of 2027; Company expects to have sufficient cash to complete its Phase III clinical trial
SGT-610 Phase III clinical trial top-line results are expected in the fourth quarter of 2026; a significant milestone in the clinical trial of recruiting more than 80% of the patients has been achieved
Sol-Gel now estimates the U.S. market potential for SGT-610 to be between $400 to $500 million annually
SGT-210 Phase 1b trial in Darier patients is ongoing; 50% of the patients have

Cosette Pharmaceuticals Announces Acquisition of Mayne Pharma, Transforming Company into a Leader in Women’s Health and Dermatology

Thu, 20 Feb 2025 17:11:00 -0400

-- Acquisition Propels Cosette Into One Of The Leading Companies In Women’s Health and Dermatology in the U.S. --

-- Highly Complementary Business Strengthens Cosette’s Portfolio, Commercial and Manufacturing Footprint and Expands Geographic Reach --

-- Utilizing Mayne Pharma’s Impressive Commercial and Sales Track Record to Drive Further Growth and Enhanced Patient Access --

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Cosette Pharmaceuticals, Inc., a U.S.-based, fully integrated, pharmaceutical company, announced today that it has entered into a definitive agreement to acquire all the outstanding shares of Mayne Pharma Group Limited (ASX: Ticker MYX) (Mayne Pharma) at AUD$7.40/share for a total

Cosette Pharmaceuticals Announces Acquisition of Mayne Pharma, Transforming Company into a Leader in Women’s Health and Dermatology

Thu, 20 Feb 2025 17:11:00 -0400

-- Acquisition Propels Cosette Into One Of The Leading Companies In Women’s Health and Dermatology in the U.S. --

-- Highly Complementary Business Strengthens Cosette’s Portfolio, Commercial and Manufacturing Footprint and Expands Geographic Reach --

-- Utilizing Mayne Pharma’s Impressive Commercial and Sales Track Record to Drive Further Growth and Enhanced Patient Access --

Cosette Pharmaceuticals Announces Acquisition of Mayne Pharma, Transforming Company into a Leader in Women’s Health and Dermatology

Thu, 20 Feb 2025 17:11:00 -0400

-- Acquisition Propels Cosette Into One Of The Leading Companies In Women’s Health and Dermatology in the U.S. --

-- Highly Complementary Business Strengthens Cosette’s Portfolio, Commercial and Manufacturing Footprint and Expands Geographic Reach --

-- Utilizing Mayne Pharma’s Impressive Commercial and Sales Track Record to Drive Further Growth and Enhanced Patient Access --

Cosette Pharmaceuticals Announces Acquisition of Mayne Pharma, Transforming Company into a Leader in Women’s Health and Dermatology

Thu, 20 Feb 2025 17:11:00 -0400

-- Acquisition Propels Cosette Into One Of The Leading Companies In Women’s Health and Dermatology in the U.S. --

-- Highly Complementary Business Strengthens Cosette’s Portfolio, Commercial and Manufacturing Footprint and Expands Geographic Reach --

-- Utilizing Mayne Pharma’s Impressive Commercial and Sales Track Record to Drive Further Growth and Enhanced Patient Access --